Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AMN107 Clear all
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

NCT03654768
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
541
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

NCT02353728
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Nilotinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 26, 2026, 3:03 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

NCT05554341
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nilotinib Hydrochloride Monohydrate, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
124
States / cities
Birmingham, Alabama • Kingman, Arizona • Palo Alto, California + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib followed by treatment-free
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
479
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01806571
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Nilotinib, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 26, 2026, 3:03 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

NCT00302016
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
AMN107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
59
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic
Interventions
Nilotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 26, 2026, 3:03 AM EDT
Terminated Phase 1 Interventional

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

NCT02225574
View directory record Official record
Conditions
Leukemia
Interventions
MEK-162, Nilotinib, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 26, 2026, 3:03 AM EDT
Terminated Phase 1 Interventional

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

NCT01751425
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 26, 2026, 3:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

NCT00644878
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

NCT00788775
View directory record Official record
Conditions
Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Santa Monica, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 26, 2026, 3:03 AM EDT
Terminated Phase 3 Interventional Results available

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00519090
View directory record Official record
Conditions
Myelogenous Leukemia
Interventions
Imatinib, Nilotinib (AMN107)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Tucson, Arizona • Anaheim, California • Baldwin Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 26, 2026, 3:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Withdrawn Phase 2 Interventional

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

NCT01670084
View directory record Official record
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 1 Interventional

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

NCT00135005
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
AMN107, STI571
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 26, 2026, 3:03 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

NCT01179737
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nilotinib, Placebo to nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

NCT01698905
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

NCT04877522
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
7 Years to 100 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

NCT00418626
View directory record Official record
Conditions
Healthy
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 1 Interventional

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

NCT00441155
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib, Imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367
View directory record Official record
Conditions
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
Interventions
Asciminib add-on, Imatinib, Nilotinib, Asciminib 80mg QD (asciminib single agent (ASAC))
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Augusta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 26, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

NCT01744665
View directory record Official record
Conditions
CML
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 26, 2026, 3:03 AM EDT
Terminated Phase 2 Interventional Results available

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

NCT02709083
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia
Interventions
Dasatinib, Imatinib Mesylate, Nilotinib
Drug
Lead sponsor
Emory University
Other
Eligibility
17 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 26, 2026, 3:03 AM EDT